Curasight A/S has successfully completed a directed issue of shares of approximately DKK 16.4 million and has entered into a new loan facility

December 12, 2025

Regulatory

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE.

Curasight A/S ("Curasight" or the "Company" – TICKER: CURAS) has, in accordance with the intention announced by the Company through a press release, on December 12, 2025, resolved on a directed issue of a total of 2,055,330 shares (the “Directed Issue”). A number of Nordic, international, institutional and professional investors participated in the Directed Issue, including both new and existing shareholders. Through the Directed Issue, Curasight receives DKK 16.4 million before transaction costs. The Directed Issue has been carried out pursuant to the authorization from the Company's general meeting to the Board of Directors under article 5.1.2 of the Company’s articles of association. The subscription price in the Directed Issue has been set at DKK 7.98 per share (the “Subscription Price”), through an accelerated bookbuilding procedure carried out by Sedermera Corporate Finance AB (“Sedermera”). Furthermore, Curasight has entered into an loan agreement with Fenja Capital II A/S (“Fenja Capital”, the “Lender”) regarding a loan facility, conditional upon an authorizing being granted by the general meeting of the Company to the Board of Directors to issue the relevant convertible loan instrument to the Lender (the “Loan Facility”, together with the Directed Issue, the “Financing”). The Financing intends to support the clinical development of uTRACE® and uTREAT® and strengthen Curasight's financial position.

The Directed Issue

The Board of Directors of Curasight has, based on authorization from the general meeting stated in article 5.1.2 of the Company’s articles of association resolved on a directed issue of 2,055,330 shares. The Subscription Price in the Directed Issue amounts to DKK 7.98 per share and has been determined through an accelerated bookbuilding procedure carried out by Sedermera. The Subscription Price corresponds to a discount of approximately 3 percent in relation to the volume weighted average price (VWAP) of the Company's share on Spotlight Stock Market during the period from and including 2025-11-17 to and including 2025-12-12.

Prior to the Directed Issue, the Company's Board of Directors has made an overall assessment and carefully considered the possibility of raising capital through a rights issue. The Board of Directors considers that the reasons for deviating from the shareholders’ pre-emption right are (i) that a rights issue would take a significantly longer time to complete and entail a higher risk for a material adverse effect on the share price, (ii) to diversify and strengthen the Company's shareholder base with Nordic, international, institutional and professional investors, and to strengthen the share's liquidity, (iii) carrying out a directed share issue can be made at lower costs and with less complexity than a rights issue and, the Board of Directors has assessed that a rights issue would also entail a risk of not being fully subscribed or necessitate significant underwriting commitments from a guarantor syndicate that would entail additional costs and/or additional dilution depending on the type of remuneration for such underwriting, and (iv) to ensure a strong balance sheet. Considering the above, the Board of Directors has made the assessment the Directed Issue with deviation from the shareholders’ pre-emptive right is the most favorable alternative for Curasight.

By establishing the Subscription Price in the Directed Issue through an accelerated bookbuilding procedure, it is the assessment of the Board of Directors that the subscription price has been determined on market terms.

Motives and use of proceeds

In order to support the clinical development of uTRACE® and uTREAT® and strengthen Curasight's financial position, the Company has chosen to carry out the Directed Issue and enter the Loan Facility. The net proceeds from the Financing are intended to be utilized as follows:

The completion of the phase 1 study with uTREAT® (brain cancer).
The completion of the phase 2 study with uTRACE® (prostate cancer).
The initiation of the phase 3 study with uTRACE® (prostate cancer), together with Curium.
Submission of an FDA Investigational New Drug (IND) application for uTREAT® in brain cancer.

The Board of Directors assesses that the net proceeds from the Financing will be sufficient to fund the Company’s operations to the end of 2026.

Loan Facility

In connection with the Directed Issue, Curasight has entered into a loan agreement with Fenja Capital regarding a loan facility, divided into two tranches. The first tranche amounts to DKK 25 million and will be structured as a convertible loan (the “Convertible Loan”), of which DKK 10 million represents a refinancing of the existing loan and DKK 15 million will be paid out upon approval by the extraordinary general meeting. The Loan Facility and the issuance of the Convertible Loan are conditional upon the general meeting of the Company resolving to authorize the Board of Directors to issue the relevant convertible loan instrument to the Lender. Curasight will separately issue a notice to convene an extraordinary general meeting with a proposal for the general meeting to authorize the Board of Directors to issue convertible loan notes. The second tranche amounts to DKK 15 million and may be drawn in Q2 2026.

The loan facility carries a setup fee of 5 percent on the total facility amount. Interest on drawn amounts accrues at 1.25 percent per started 30-day period, while interest on undrawn amounts accrues at 0.4 percent per started 30-day period. The Loan facility has a maturity date of 2026-12-29, with a total convertible size of DKK 25 million. The conversion price is set at 125 percent of the subscription price in the Directed Issue.

Number of shares, share capital and dilution
Through the Directed Issue, the Company's share capital will increase by DKK 102,766.50, from DKK 2,293,375.55 to DKK 2,396,142.05, through a new issue of 2,055,330 shares, which means that the total number of shares will increase from 45,867,511 shares to 47,922,841 shares and will result in a dilution of approximately 4.29 percent of the capital for existing shareholders who did not participate in the issue.

Advisors

Sedermera Corporate Finance AB acts as Sole Global Coordinator and bookrunner in connection with the Directed Issue. DLA Piper is the Company's legal advisor.

This disclosure contains information that Curasight is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 12-12-2025 22:38 CET.

For more information about the Directed Issue, please contact:

Sedermera Corporate Finance AB

Phone: +46 (0)40 615 14 10

E-mail: [email protected]

www.sedermera.se

For further information about the Company, please contact:

Ulrich Krasilnikoff, CEO, Curasight A/S

Phone: +45 22 83 01 60

E-mail: [email protected]

www.curasight.com

Downloads

Release

Important information

The publication, release or distribution of this press release may be restricted in certain jurisdictions. Recipients of this press release in jurisdictions where this press release has been published or distributed should inform themselves about and observe any such restrictions. This announcement does not constitute an offer to the public, or a solicitation of any offer, to buy or subscribe for any securities of the Company in any jurisdiction. This document has not been approved by any authority in any jurisdiction and does not constitute a prospectus within the meaning of Regulation (EU) 2017/1129 (the "Prospectus Regulation"). No prospectus has been or will be prepared in connection with the Directed Issue. In any EEA Member State, this communication is only addressed to and is only directed at "qualified investors" in that Member State within the meaning of the Prospectus Regulation.

The information contained in this press release is for background purposes only and does not purport to be full or complete. No reliance may or should be placed by any person for any purpose on the information contained herein or its accuracy or completeness. Neither the Company nor any of its affiliates, advisors or representatives accepts any responsibility or liability whatsoever for, or makes any representation or warranty, express or implied, as to the truth, accuracy or completeness of the information in this press release (or whether any information has been omitted).

The information in this press release may not be announced, published, copied or distributed, directly or indirectly, in the United States, Canada, Japan, Australia, Hong Kong, New Zealand, Singapore, Belarus, Russia, South Africa or any other jurisdiction where the announcement, publication or distribution of the information would not comply with applicable laws and regulations or would require a prospectus, registration or other measures than those required by Danish law.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, registration under the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of such securities in the United States.

This announcement does not constitute an invitation to underwrite, subscribe for or otherwise acquire or dispose of any securities in any jurisdiction. This press release does not constitute a recommendation for any investor's decision regarding the Directed Issue. Each investor or potential investor should conduct its own investigation, analysis and evaluation of the business and information described in this press release and any publicly available information. The price and value of the securities may go down as well as up and past performance is no guide to future results. Neither the contents of the Company's website nor any other website accessible through hyperlinks on the Company's website are incorporated into or form part of this press release. 

Forward-looking statements
This press release contains forward-looking statements that reflect the Company's intentions, beliefs or expectations regarding the Company's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and can be identified by the use of words such as "believes", "expects", "anticipates", "intends", "estimates", "will", "may", "anticipates", "should", "could" and, in each case, the negatives thereof, or similar expressions. The forward-looking statements in this press release are based on various assumptions, many of which are based on additional assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there can be no assurance that they will materialize or that they are accurate. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, actual results or outcomes could differ materially from those in the forward-looking statements for a variety of reasons. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this press release by the forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements contained in this press release are accurate and any reader of this press release should not place undue reliance on the forward-looking statements contained in this press release. The information, opinions and forward-looking statements expressed or implied herein are made only as of the date of this press release and may be subject to change.

About Curasight

Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE^®) and Radioligand Therapy (uTREAT^®) Theranostic Platform targeting the urokinase-type plasminogen activator receptor ("uPAR"). The technology is expected to improve diagnosis and provide more gentle and efficient treatment of multiple cancer types.